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A series of 2-arylbenzoxazole compounds possessing a cytotoxic activity as potential anticancer agents has been 
synthesised. Oxidative coupling of benzaldehyde with o-aminophenol utilizing lead tetraacetate approach has been used to 
realize the synthesis of compounds 1-11. The cytotoxicity of 1-11 have been screened against breast cancer cell line MCF-7 and 
human colon cancer cell line HCT-116 utilizing doxorubicin as reference drug. Among these compounds, 2-(3-
benzyloxyphenyl)benzoxazole-5-acetic acid 5 and 2-(4-methoxyphenyl)benzoxazol-5-acetic acid 10, are found to be promising 
cytotoxic compounds against MCF-7 cell line. In addition, this study shows that the presence of acetic acid group at position 5 
of benzoxazole nucleus enhances the activity. Moreover, it is noticed that the presence of oxygen atom directly linked to the 
phenyl substituent improves activity. The results offer a new benzoxazole based template to design and develop novel 
antineoplastic agents. 
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The discovery of novel, effective and safe anticancer 
compounds represents a great challenge for researchers 
despite the long time and efforts that have been spent to 
achieve this objective. The existing anticancer agents 
are still far from optimum. This fact is reflected with 
the number of deaths caused by cancer as well as by 
the toxic effects of the existing anticancer drugs
1
. 
Literature showed that 2-arylbenzoxazoles possess a 
very wide range of biological activities including 
anticancer activities
2-4
. Some of the reported 
benzoxazoles with antitumor activities are presented in 
Figure 1. Ueki et al. isolated a benzoxazole, UK-1, as a 
novel cytotoxic antibiotic produced from streptomyces 
sp. 517-2, which exhibits inhibitory activity against 
various cancer cells
5
. Based on UK-1, Kumar
6
 and co-
workers reported the synthesis of a structural analogue 
of UK-1, compound IA, which showed to maintain 
selectivity and activity against cancer cells lines MCF-
7 and HT-29, with IC50 values in the 1.5 & 9.1 µM, 
respectively. In another work, the 5- flourobenzoxazole 
2A exhibits potent activity in vitro, submicromolar, in 
tow cell lines (GI50 = 0.36 µM and 0.27 µM on MCF-7 
and MDA 468)
7
. In addition, The 5-aminolbenzoxazole 
compound 3A demonstrated to be active against some 
cancer cell lines
8
. More recently, Al-Harthy et al.
9
 
investigated the potential anticancer activity of some 2-
methyl benzoxazoles upon testing them against human 
A-549 lung carcinoma cells. Also Khajondetchairit 
et al.
10
 reported a very potent arylbenzoxazoles with 
IC50 of 3.3 μM in the KB cell line. 
On the other hand, some arylbenzoxazole derivatives 
have been tested as topoisomerase II inhibitors which in 
known to be as potential drug target, and its inhibition 
have become important strategy in the treatment of 
neoplastic diseases. In this context, Pinar and co-workers 
tested the efficiency of a series of benzoxazoles as 
eukaryotic topoisomerase II inhibitors. Their study 
showed that several 2-arylbenzoxazole derivatives had 
significant inhibition activities on topoisomerase II 
enzyme, and among these compounds, 4A was found to 
be more potent than the reference drug etoposide (IC50 
value = 18.8 µM, Figure 1)
11
. While Oksuzoglu et al.
12
 
showed that 5-chlorotolylbenzoxazole 5A was to be 
significant DNA topoisomerase II inhibitor (IC50 value = 
22.3 µM). As reported in literature review mentioned 
above, the 2- arylbenzoxazole scaffold can tolerate a 
wide range of substituents without compromising the 
anticancer activities. The tolerability of benzoxazole 
nucleus could be attributed to a different biomolecular 
targets that it's possibly interacts with. 
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In this study, a number of 2-arylbenzoxazole-5-
acetic acid derivatives were synthesized, 
characterized and their cytotoxic activities were 
biologically evaluated in vitro against MCF-7 and 
HCT-116 cell lines.  
Results and Discussion 
Synthetic chemistry 
A novel series of 2-arylbenzoxazole derivatives were 
designed and synthezied as cytotoxic agents. According 
to literature, several synthetic methods are available to 
prepare 2-arylbenzoxazole target compounds
13
. 
Oxidative coupling of benzaldehyde with o-
aminophenol utilizing lead tetraacetate represents one of 
these synthetic methods. Although it is not among the 
popular methods, possibly due to the oxidative power of 
lead tetraacetate
14,15
. It is reported that lead tetraacaetae 




The unwanted reactivity of lead tetraacetate could be 
minimized by either avoiding compounds with 
susceptible groups and by using protective strategy. In 
our synthetic attempts, we found that the presence of 
hydroxyl groups as well as free carboxylic acid groups 
decreases the yield dramatically. In such cases, using 
protective groups would be helpful; therefore, in order 
to prepare carboxylic acid compounds, we block the 
carboxylic acid groups by converting them to the 
corresponding methyl ester derivatives, and then the 
oxidative coupling was achieved. The deprotection of 
carboxylic acids was achieved by hydrolysis of ester 
with NaOH solution in ethanol followed by 
acidification with concentrated HCl (Scheme I). 
Cytotoxicity 
The synthesized benzoxazole derivatives were 
biologically evaluated in vitro for their anticancer 
activity. In order to examine the cytotoxic activity of 
compounds 1-11 (Table I), we performed cell 
viability analysis on two cancers cell lines, namely 
breast (MCF-7) and colorectal (HCT-116). The 
anticancer agent doxorubicin was used as the standard 
reference to compare their cytotoxic activity. Cells 
were incubated with the compounds at different 
concentrations that range between 0-200 μg/mL for 
72 hours and then cell growth was evaluated using 
MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide) assay. If no cytotoxicity was 
observed at 200 μg/mL, the compound was assumed 
to have no cytotoxic activity against the two types of 
cancerous cell lines and it is represented as resistant 
(R) in Table I. Table I summarizes the results of
Figure 1 — Some benzoxazoles with anticancer activities 
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cytotoxicity tests against MCF-7 and HCT-116 cell 
lines.  
From the obtained results, as can be seen from 
Table I, compounds 5, 6, 10 and 11 demonstrates 
potent anti-proliferative activities against MCF-7 cell 
line, while, compounds 10 and 11 exhibits potent 
cytotoxic activities against HCT-116 cell line, and 
these results shows that previously mentioned 
compounds can be considered as promising 
antineoplastic agents. Conclusions were supported by 
comparing the IC50 s of the tested compounds with the 
IC50 of doxorubicin obtained under the same 
conditions (Table I). For example, compound 5 
exhibits one tenth the activity of doxorubicin on 
MCF-7 cell line which means that optimization of 5 
could yield a compound with comparable activity 
with doxorubicin. Unlike doxorubicin, 5, 6, 10 and 11 
shows higher selectivity against MCF-7 compared to 
their activity against HCT-116.  
Regarding a hypothesized structure-activity 
relationships (SAR) that could be concluded from our 
work, it seems that the presence of acetic acid moiety or 
its methyl ester at position 5 enhances the cytotoxic 
activity of arylbenzaoxazole scaffold. This can be 
noticed by comparing 4-methoxyphenyl-5-
flurobenzoxazole (compound 6A shown in Figure 2) 
with IC50 value of 22.7 µM on MCF7 with compound 
10, which possess acetic acid group instead of fluoro 




On the other hand, it seems that the presence of 
oxygen atom at positions 3 or 4 (on the phenyl group) 
potentiate the activity unlike the presence of nitro, fluoro 
and amino substituents. Additionally, this study show 
that compounds with free carboxylic group (1, 5 and 10) 
Scheme I — Synthesis of 2-arylbenzoxazole derivatives 1-11 
Table I — Growth inhibitory activity of compounds 1-11 and the 
reference drug doxorubicin, against human cancer MCF-7 and 





Doxorubicin 0.13 0.12 
1 14.30 41.95 
2 57.31 58.35 
3 121.31 15.02 
4 84.70 20.00 
5 1.49 84.54 
6 5.24 40.03 
7 R R 
8 R R 
9 R R 
10 2.02 4.26 
11 3.41 5.98 
R, resistant. 
Figure 2 — Structure of compound 6A 




are more active than their corresponding methyl esters 
on MCF-7 cells, while the HCT-116 cells seem to be 
insensitive to this variation. Compounds 5 and 6, 
which have oxygen atom at position 3 exhibit higher 
selectivity against MCF-7 compared to HCT-116. 
Furthermore, the ester derivative 2 shows no 
selectivity, while its acid derivative 1 exhibits high 
selectivity against MCF-7. The ester 11 doesn’t 
differentiate much between the two cell lines. Among 
the tested compounds, 3 and its methyl ester 4 
exhibits significant higher activity against HCT-116 
compared to MCF-7. Concerning the possibility that 
the mechanism of action of tested compounds to be by 
the inhibition of topoisomerase II, previous studies 
showed that the presence of nitro and amino group at 
position 4 (on the phenyl group) decreases 
topoisomerase II inhibition activity.  
At the best of our knowledge, all the previously 
reported arylbenzoxazoles that showed good cytotoxic 
activities, they did not contain alkanoic moiety on the 
benzoxazole ring. Therefore, this is the first study to 
demonstrate that the presence of acetic/acetate moiety 
attached to the benzoxazole ring potentiates the 
cytotoxic activity. Concluding, synthesized 
compounds in this work as 5, 6, 10 and 11 were found 
to possess strong anti-proliferative activity and may 
provide promising opportunities to design and 
develop novel antineoplastic agents.  
 
Materials and methods 
 
Reagents and chemicals 
All chemical reagents were purchased from 
commercially available sources and utilized without 
purification. 
1
H NMR spectra were obtained using a 
Varian Utility 300 spectrometer (Varian Medical 
systems Inc, Palo Alto, CA, USA), and chemical 
shifts were reported as parts per million (ppm) 
relative to internal standard TMS. FT-IR spectra were 
obtained with a Nicolet Impact 410 (Nicolet 
Instrument Corp, Fitchburg, WI, USA). Mass 
spectrometry (MS) data were obtained by VG 7070 
mass spectrometer (M-scan Inc, West Chester PA, 
USA). 
 
General method for the synthesis of the tested 
compounds 1-11  
2-arylbenzoxazole-5-acetic acids and their methyl 
esters (compounds 1-11 shown in Scheme I) were 
prepared as following: methyl ester derivatives were 
firstly prepared by addition of equimolar amount of 
methyl 3-amino-4-hydroxyphenylacetate to a solution 
of the suitably substituted benzaldehyde in absolute 
ethanol. The formed solution was heated under reflux 
for about 4 h. The ethanol was evaporated to give 
thick product which was dissolved in hot glacial 
acetic acid. Suitable amount of lead tetraacetate was 
added, and the mixture was allowed to cool to RT 
yielding solid precipitate which was collected by 
filtration. Purification of the final product, if required, 
can be achieved by recrystallization from hot ethanol. 
To get the corresponding acids, hydrolysis of the 
methyl esters were performed by stirring a solution of 
the methyl ester compounds in suitable volume of 
NaOH solution in 90% ethanol at RT for 3 h. During 
this time a solid was formed and it was collected on a 
Buchner funnel, washed with acetone, and dissolved 
in suitable amount of H2O. The aqueous solution was 
acidified with concentrated HCl giving a solid 
precipitate which was collected and purified by 
recrystallization from aqueous ethanol. 
 
Cytotoxicity 
Human cell cultures: human breast cancer cells 
(MCF-7) and human colorectal carcinoma cells 
(HCT-116) were obtained from the American Type 
Culture Collection (ATCC). They were grown as 
monolayer's in T75 flasks at 37°C in a humidified 
atmosphere with 5% CO2 in Dulbecco's modified 
Eagle's medium (DMEM) (Capricorn Scientific, 
Germany) supplemented with 10% (v/v) fetal bovine 
serum and 1% penicillin-streptomycin (EuroClone 
Diagnostica, Italy). Cell lines were split twice weekly 
with 0.25% trypsin (EuroClone Diagnostica, Italy). 
 
MTT Cell Proliferation Assay 
Cells were plated at 10,000 cells per well in a 96-well 
plate and incubated overnight in DMEM and 
subsequently treated with the compounds at various 
concentrations starting with 100 µg/mL followed by 
two-fold dilutions. The cell viability was measured after 
72 h post-treatment to determine the IC50 of each 
compound. By the end of the incubation period, 20 µL 
of MTT solution (5 mg/mL, Calbiochem, Darmstadt, 
Germany) was added to each well and incubated for 
three hours until purple precipitate became visible. The 
solution was removed and 200 µl of dimethyl sulfoxide 
(DMSO) was then added to each well to dissolve the 
crystals. The plates were then read using a microtiter 
plate reader at the wavelength of 570 nm (Bio-tek 
Instruments). Triplicates were carried out for each cell 
line. Equation 1 formula was used to determine the 
percentage of viable cells:  














2-( 3-Hydroxy-4-nitrophenyl) benzoxazole-5-acetic 
acid, 1 
Yield 9%. m.p.249-250°C. 
1
H NMR (DMSO-d6): δ 
3.74 (s, 2H, benzylic CH2), 7.38 (d, 1H, ArH), 7.73 (m, 
3H, ArH), 7.91( s, 1H, ArH), 8.08 (d, 1H, ArH), 11.58 
(br, 1H), 12.39 (br, 1H); MS: m/z 315. 
Methyl 2-(3-hydroxy-4-nitrophenyl) benzoxazole-
5-acetate, 2 
Yield 30%. m.p.176-179°C. 
1
H NMR (CDCl3): δ 
3.6 (s, 3H, OCH3), 3.86 (s, 2H, benzylic CH2), 7.4 (d, 
1H, ArH), 7.76 (m, 3H, ArH), 7.91(s, 1H, ArH), 8.07 
(d, 1H, ArH); MS: m/z 329. 
 
2-(4-Methylyphenyl) benzoxazole-5-acetic acid, 3 
Yield 61%. m.p.164-166°C. 
1
H NMR (DMSO-d6): 
δ 2.43 (s, 3H, CH3), 3.80 (s, 2H, benzylic CH2), 7.09 
(d, 2H, ArH, J = 10 Hz), 7.30 (dd, 1H, ArH), 7.58 (d, 
2H, ArH), 7.74 (d, 1H, ArH), 7.78 (d, 2H, ArH), 8.19 
(d, 2H, ArH); MS: m/z 268. 
 
Methyl 2-(4-methylyphenyl) benzoxazole-5-acetate, 4 
Yield 53%. m.p.146-148°C. 
1
H NMR (DMSO-d6): 
δ 2.45 (s, 3H, ArCH3), 3.65 (s, 3H, OCH3), 3.85 (s, 
2H, benzylic CH2), 4.65 (s, 3H, ArCH3), 7.09 (d, 2H, 
ArH, J = 10 Hz), 7.30 (dd, 1H, ArH), 7.58 (d, 2H, 
ArH), 7.74 (d, 1H, ArH), 7.78 (d, 2H, ArH), 8.19 (d, 
2H, ArH); MS: m/z 282. 
 
2-(3-Benzyloxyphenyl) benzoxazole-5-acetic acid, 5 
Yield 57%. m.p.194-195°C. 
1
H NMR: (DMSO-d6): 
δ 3.68 (s, 2H, benzylic CH2), 5.19 (s, 2H, 
ArOCH2Ph), 7.42 (m, 12H, ArH), 12.27 (br, 1H, 




Yield 69%. m.p.130-131°C. 
1
H NMR: (DMF-d7): 
δ 3.7 (s, 3H, COOCH3), 3.9 (s, 2H, benzylic CH2), 
5.32 (s, 2H, PhCH2OR), 7.62 (m, 12H, ArH), MS: m/z 
3757. 
 
Methyl 2-(4-aminophenyl) benzoxazole-5-acetate, 7 
Yield 70%. m.p.185-186°C ; 
1
H NMR: (CDCl3): δ 
3.65 (s, 3H, OCH3), 3.75 (s, 2H, CH2), 4.0 (s, 2H, 
NH2), 6.75 (d, 2H, ArH), 7.15 (dd, 1H, ArH), 7.45 (d, 
1H, ArH), 7.6 (d, ArH), 8.05 (d, 2H, ArH);  
MS: m/z 283. 
Methyl- 2-(3-fluoro-4-nitrophenyl) benzoxazole-5-
acetate, 8 
Yield 66%. m.p.136-141°C. 
1
H NMR: (CDCl3): δ 
3.6 (s, 3H, OCH3), 3.86 (s, 2H, benzylic CH2), 7.4 (d, 
1H, ArH), 7.76 (m, 3H, ArH), 7.91(s, 1H, ArH), 8.07 
(d, 1H, ArH); MS: m/z 331. 
 
Methyl 2-(4-nitrophenyl) benzoxazole-5-acetate, 9 
Yield: 82%. m.p.195-196°C. 
1
H NMR: (CDCl3): δ 
3.5 (s, 3H, OCH3), 3.7 (s, 2H, CH2), 7.3 (d, 1H, ArH, 
J= 8.43 Hz), 7.6 (d, 1H, ArH, J = 8.4 Hz), 7.75 (s, 1H, 
ArH), 8.4 (m, 4H, ArH); MS: m/z 313. 
 
2-(4-Methoxyphenyl) benzoxazole-5-acetic acid, 10 
Yield: 80%. m.p.112-115°C. 
1
H NMR: (CDCl3): δ 
3.74 (s, 2H, CH2), 3.80 (s, 3H, OCH3), 7.10 (d, 2H, 
ArH, J = 10 Hz), 7.27 (dd, 1H, ArH), 7.50 (d, 1H, 
ArH, J = 10 Hz), 7.70 (s, 1H, ArH), 8.21 (d, 2H, ArH, 
J = 10 Hz); MS: m/z 283. 
 
Methyl 2-(4-methoxyphenyl) benzoxazole-5-acetate, 
11 
Yield 50%. m.p.103-105°C. 
1
H NMR: (CDCl3): δ 
3.60 (s, 3H, COOCH3), 3.72 (s, 2H, CH2), 3.85 (s, 3H, 
OCH3), 6.99 (d, 2H, ArH, J = 10 Hz), 7.2 (dd, 1H, 
ArH), 7.46 (d, 1H, ArH, J = 10 Hz), 7.61 (s, 1H, 
ArH), 8.15 (d, 2H, ArH, J = 10 Hz); MS: m/z 297. 
 
Conclusion 
A series of 2-arylbenzoxazole derivatives were 
synthesized using oxidative coupling of the suitably 
substituted benzaldehyde with methyl ester of 3-amino-
4-hydroxyphenylacetates. The cytotoxicity of 
synthesized compounds was evaluated using MTT assay 
and the IC50 for each compound was reported. The 
findings of this study showed that some compounds (10 
& 11) exhibit promising activity in both cancer cell lines 
(MCF-7 & HCT-116), while 5 and 6 demonstrate 
significant activity against MCF-7 cancer cell line. 
These results offer a new benzoxazole based template to 
design and develop novel antineoplastic agents, 
therefore, additional in vitro and in vivo studies are 
required to reveal their possible mechanism of action.  
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